MicroRNA与弥漫大B淋巴瘤预后关系的系统综述和Meta分析

目的 综合分析不同的微小RNA （microRNAs，miRs）对弥漫大B淋巴瘤（diffuse large B cell lymphoma，DLBCL）的预后价值。方法 计算机检索2007年1月~2017年7月收录在万方数据库、维普中文科技期刊全文数据库、中国期刊全文数据库、PubMed数据库和Embase数据库的相关文献，筛选后采用Stata 12.0进行Meta分析。结果 最终纳入30篇文献，2 574研究对象。综合分析发现，miR-21的低表达降低了DLBCL患者的无复发生存期（relapse free survival，RFS）（HR=0.61，95% CI:0.40~0.94，P=0.024）；miR-155的高表达降低了DLBCL患者的无进展生存期（progress free survival，PFS）（HR=2.50，95% CI:1.54~4.06，P<0.001）；miR-222的高表达降低了DLBCL患者的PFS （HR=2.33，95% CI:1.53~3.57，P<0.001）。结论 基于所有分析结果可知，miR特别是miR-21，miR-222和miR-155是影响DLBCL的RFS和PFS重要预后因子。

A systematic review and Meta-analysis on the relationship between microRNAs and prognosis in diffuse large B-cell lymphoma

Objective To comprehensively analyze the prognostic value of different microRNAs (miRs) in diffuse large B-cell lymphoma(DLBCL).Methods A computerized retrieval was carried out by using Wanfang data,VIP databases,CNKI, PubMed and Embase databases to collect the relevant literatures published from January 2007 to July 2007.By screening, Meta-analysis was performed with Stata 12.0 software.Results Thirty literatures comprised 2 574 cases were included. Comprehensive analysis revealed that decreased expression of miR-21 was associated with shorter relapse-free survival(RFS)in DLBCL(HR=0.61,95% CI:0.40-0.94, P=0.024). Increased expression of miR-155 was associated with shorter progression-free survival(PFS)(HR=2.50,95% CI:1.54-4.06, P<0.001). Increased expression of miR-222 was associated with shorter PFS(HR=2.33,95% CI:1.53-3.57, P<0.001).Conclusions According to the results, it can be concluded that miRs especially miR-21,miR-155 and miR-222 are valuable prognostic predictors in DLBCL of recurrence free survival and progression free survival period.